Composition : Lapatinib (250 mg) Tablet
Dosage Form : Tablet
Packaging Type : in a Bottle
Packaging : 30 Tablets
Price : ₹1/-
Please Contact For Best Price
LAPANIB 250 Tablet (Lapatinib 250 mg) is a highly specialized, oral, targeted cancer medicine classified as a Dual Tyrosine Kinase Inhibitor (TKI). It is a critical treatment component for patients diagnosed with HER2-positive advanced or metastatic breast cancer.
Mechanism and Impact:Lapatinib works by selectively and reversibly binding to the intracellular domain of two key receptors: Human Epidermal Growth Factor Receptor 2 (HER2) and Epidermal Growth Factor Receptor (EGFR). By competitively blocking the signaling pathways, Lapatinib effectively halts the uncontrolled tumor cell growth. This dual-action mechanism is particularly valuable in treating cancers that have progressed following treatment with other HER2-targeted agents.
Key Therapeutic Uses (Combination Therapy):
-
With Capecitabine: For patients whose cancer has progressed after prior therapy including an anthracycline, a taxane, and trastuzumab.
-
With Letrozole: For postmenopausal women with hormone receptor-positive and HER2-positive metastatic breast cancer.
We offer an exclusive PCD Pharma Franchise opportunity for LAPANIB 250, providing partners with monopoly rights in this specialized, high-demand segment of targeted breast cancer therapeutics.
Read More